Trade Report: Today, Adamas Pharmaceuticals Inc. (ADMS) Stock Rating Upgraded by Zacks Investment Research

Today, Adamas Pharmaceuticals Inc. (ADMS) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Other research analysts have also recently issued research reports about the stock. Mizuho upgraded shares of Adamas Pharmaceuticals from a neutral rating to a buy rating in a report on Monday, June 13th. Credit Suisse Group AG restated a buy rating and issued a $21.00 target price on shares of Adamas Pharmaceuticals in a report on Monday, July 25th. Noble Financial restated a buy rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a report on Friday, July 22nd. Needham & Company LLC reiterated a buy rating and issued a $38.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, July 20th. Finally, JMP Securities reiterated a buy rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Adamas Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $32.11.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 14.45 on Tuesday. Adamas Pharmaceuticals has a 12 month low of $12.02 and a 12 month high of $31.84. The stock has a 50 day moving average of $16.01 and a 200 day moving average of $15.81. The firm’s market cap is $316.87 million.

In other news, Director William W. Ericson acquired 43,719 shares of the business’s stock in a transaction on Friday, September 2nd. The stock was bought at an average price of $14.75 per share, for a total transaction of $644,855.25. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Ix Lp Mdv acquired 62,977 shares of the business’s stock in a transaction on Friday, September 16th. The shares were purchased at an average price of $16.48 per share, with a total value of $1,037,860.96. The disclosure for this purchase can be found here. Company insiders own 31.79% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. American International Group Inc. increased its position in shares of Adamas Pharmaceuticals by 57.9% in the second quarter. American International Group Inc. now owns 9,613 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 3,526 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in shares of Adamas Pharmaceuticals during the second quarter worth about $158,000. Highbridge Capital Management LLC bought a new position in shares of Adamas Pharmaceuticals during the second quarter worth about $205,000. ProShare Advisors LLC increased its position in shares of Adamas Pharmaceuticals by 4.6% in the second quarter. ProShare Advisors LLC now owns 18,138 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 794 shares in the last quarter. Finally, Teachers Advisors Inc. increased its position in shares of Adamas Pharmaceuticals by 58.0% in the second quarter. Teachers Advisors Inc. now owns 26,961 shares of the specialty pharmaceutical company’s stock worth $408,000 after buying an additional 9,894 shares in the last quarter. Institutional investors own 74.65% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Related posts

Leave a Comment